Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Heidelberg, Germany, May 8, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on May 15, 2018, the Company will release its financial results for the quarter ended March 31, 2018. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Tuesday, May 15, 2018 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3326332.
United States: +1 720-543-0214
Germany: +49 (0)89 20303 5709
Netherlands: +31 (0) 20 721 9251
Denmark: +45 35 15 80 49
France: +33 (0)1 76 77 22 74
Switzerland: +41 (0)22 567 5729
United Kingdom: +44 (0)330 336 9105
An audio webcast of the conference call can be accessed in the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], [email protected]
